Abstract
Lung adenocarcinomas are for the majority of patients diagnosed at the stage of generalized disease, where systemic therapy plays the primary role. Chemotherapy remains the fundamental modality for most of the patients of first-line treatment.
Its effectiveness can be further enhanced by angiogenesis inhibitors. The situation is changing in the second line treatment - immunotherapy plays important role in these cases, although direct comparison with more efficient combinations of docetaxel with angionegesis inhibitors has not been done yet.
Targeted therapy has found its place for patients with proven sensitive EGFR mutations or translocations of genes ALK or ROS1. Moreover, in case of resistance to the first line drugs, the next generation medication can be used in some cases.
In addition, numerous studies are in progress - they could bring another step to improve prognosis of those patients.